Oral GLP‑1 market shifts
Lilly’s oral GLP‑1, Foundayo, got FDA attention this week — a direct entrant into the oral obesity/diabetes space that changes competitive dynamics for prescribers and analytics teams tracking real‑world outcomes. (Web briefing: Foundayo enters oral GLP‑1 market) (businesstoday.in).
The U.S. Food and Drug Administration approved Eli Lilly’s oral weight‑loss pill Foundayo (generic name orforglipron) on April 1, 2026, and Lilly said prescriptions are being accepted immediately with shipments from LillyDirect starting April 6. (fda.gov) (biospace.com) Foundayo joins a second daily oral pill option to the market after Novo Nordisk’s oral Wegovy pill was approved on December 22, 2025, and the two drugs differ in practical use: Lilly says Foundayo can be taken any time of day without food or water restrictions, while Novo’s oral semaglutide pill has morning fasting/administration requirements. (prnewswire.com) (biospace.com) Drugs in this class act by copying a naturally released gut hormone that reduces hunger and slows how quickly the stomach empties after a meal; that combination lowers calorie intake and helps control blood sugar over time. (nature.com) (my.clevelandclinic.org) Orforglipron is a small‑molecule, non‑peptide medicine that binds the same receptor as peptide injectables but does so with a “partial agonist” profile — meaning it activates the receptor less strongly than a full activator — and Lilly describes a signaling bias favoring a cell messenger called cyclic AMP over a pathway known as beta‑arrestin; those pharmacologic differences explain why orforglipron can be formulated as a once‑daily tablet without the fasting rules used for some oral peptides. (mdpi.com) (medical.lilly.com) Clinical readouts: in the ATTAIN‑1 trial people who stayed on the highest dose of Foundayo lost an average of 27.3 pounds (12.4% of body weight), while Lilly’s head‑to‑head ACHIEVE‑3 trial against oral semaglutide reported greater blood‑sugar reductions (A1C fell 2.2% with orforglipron 36 mg vs 1.4% with oral semaglutide 14 mg) and larger weight drops at 52 weeks (9.2% vs 5.3% for the efficacy estimand). (biospace.com) (prnewswire.com) Regulatory and rollout specifics that affect prescribing and data capture: the agency approved Foundayo under a national priority review pathway and set a titration schedule that starts at 0.8 mg and increases roughly every 30 days up to higher doses (listed up to 17.2 mg), Lilly plans commercial access programs with starting patient prices reported at $25 per month with commercial coverage and $149 for self‑pay, and broad pharmacy availability follows the initial LillyDirect shipping. (fda.gov) (biospace.com)
